These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 12455399)
1. New approaches for antigen discovery, production and delivery: vaccines for veterinary and human use. Potter AA; Babiuk LA Curr Drug Targets Infect Disord; 2001 Nov; 1(3):249-62. PubMed ID: 12455399 [TBL] [Abstract][Full Text] [Related]
4. Bovine adenovirus-3 as a vaccine delivery vehicle. Ayalew LE; Kumar P; Gaba A; Makadiya N; Tikoo SK Vaccine; 2015 Jan; 33(4):493-9. PubMed ID: 25498212 [TBL] [Abstract][Full Text] [Related]
5. Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z; Leong KW J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136 [TBL] [Abstract][Full Text] [Related]
6. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature. Mrsny RJ J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692 [TBL] [Abstract][Full Text] [Related]
7. Delivery of antigens used for vaccination: recent advances and challenges. Scherliess R Ther Deliv; 2011 Oct; 2(10):1351-68. PubMed ID: 22826888 [TBL] [Abstract][Full Text] [Related]
8. Fish vaccine antigens produced or delivered by recombinant DNA technologies. Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855 [TBL] [Abstract][Full Text] [Related]
10. Adjuvants for veterinary vaccines--types and modes of action. Gerdts V Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):456-63. PubMed ID: 26697712 [TBL] [Abstract][Full Text] [Related]
11. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Mills KH Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777 [TBL] [Abstract][Full Text] [Related]
14. Broadening the approaches to developing more effective vaccines. Babiuk LA Vaccine; 1999 Mar; 17(13-14):1587-95. PubMed ID: 10194810 [TBL] [Abstract][Full Text] [Related]
15. Innovative vaccine production technologies: the evolution and value of vaccine production technologies. Bae K; Choi J; Jang Y; Ahn S; Hur B Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. Babiuk S; Baca-Estrada M; Babiuk LA; Ewen C; Foldvari M J Control Release; 2000 May; 66(2-3):199-214. PubMed ID: 10742580 [TBL] [Abstract][Full Text] [Related]
17. A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery. Griffin JF Adv Drug Deliv Rev; 2002 Oct; 54(6):851-61. PubMed ID: 12363434 [TBL] [Abstract][Full Text] [Related]
18. The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines. Pezeshki A; Ovsyannikova IG; McKinney BA; Poland GA; Kennedy RB Expert Rev Vaccines; 2019 Mar; 18(3):253-267. PubMed ID: 30700167 [TBL] [Abstract][Full Text] [Related]
19. Vaccines for the future: learning from human immunology. De Gregorio E; Rappuoli R Microb Biotechnol; 2012 Mar; 5(2):149-55. PubMed ID: 21880117 [TBL] [Abstract][Full Text] [Related]
20. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]